CinDome Pharma, a subsidiary of CinRx Pharma, announced a $40 million Series B financing extension from existing investors Perceptive Advisors and CinRx Pharma, raising the total Series B to $59 million.

The funds are earmarked to support the development of deudomperidone (CIN‑102), including ongoing enrolment and evaluation in its Phase 2 envision3D trial for diabetic gastroparesis and to position the therapy for future registrational trials. Deudomperidone is a novel deuterated formulation of domperidone, engineered to maintain gastric efficacy while significantly reducing cardiac QT risk. It has shown a positive safety profile, with no drug-related adverse events or meaningful laboratory abnormalities, has negligible QT impact at high exposures, and has demonstrated target engagement and improved gastric emptying in Phase 2a testing.